Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $19,385 | $16,526 | $24,468 | $29,115 |
| G&A Expenses | $8,163 | $6,881 | $8,097 | $9,515 |
| SG&A Expenses | $8,163 | $6,881 | $8,097 | $9,515 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27,548 | $23,407 | $32,565 | $38,630 |
| Operating Income | -$27,548 | -$23,407 | -$32,565 | -$38,630 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$34,745 | -$3,622 | -$8,742 | -$4,611 |
| Pre-Tax Income | -$62,293 | -$27,029 | -$41,307 | -$43,241 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$62,293 | -$27,029 | -$41,307 | -$43,241 |
| % Margin | – | – | – | – |
| EPS | -1.02 | -0.563 | -0.89 | -1.03 |
| % Growth | -81.2% | 36.8% | 13.6% | – |
| EPS Diluted | -1.02 | -0.563 | -0.89 | -1.03 |
| Weighted Avg Shares Out | 60,985 | 48,025 | 46,554 | 41,854 |
| Weighted Avg Shares Out Dil | 60,985 | 48,025 | 46,554 | 41,854 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,824 | $1,584 | $654 | $0 |
| Interest Expense | $0 | $0 | $0 | $15 |
| Depreciation & Amortization | $85 | $151 | $367 | $460 |
| EBITDA | -$27,463 | -$23,256 | -$32,198 | -$38,170 |
| % Margin | – | – | – | – |